Compare Incyte Corporation (INCY) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Skyworks Solutions Inc — how do they compare? Incyte Corporation trades at $118.05 (market cap $23.11B), while Skyworks Solutions Inc trades at $63.18 (market cap $8.99B). The key difference: Incyte Corporation is far larger — about 2.6× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays a 4.75% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SWKS | |
|---|---|---|
Market Cap | $23.11B | $8.99B |
Sector | Health | Technology |
52-Week High | $118.52 | $83.40 |
52-Week Low | $67.38 | $52.50 |
Enterprise Value | $19.13B | $8.76B |
Dividend Yield | — | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Skyworks Solutions (SWKS) trades at $59.83, up 0.88% on the day, with a bearish technical signal but strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue has declined from $5.5B in 2022 to $4.1B in 2025, though profitability metrics like a 41.08% gross margin remain solid. Recent news highlights product launches in AI and EV sectors and an ongoing legal investigation.
The outlook is mixed: analyst consensus is bullish with a $75.88 price target (58.34% buy ratings), but technicals and declining revenue pose risks. Key opportunities include diversification beyond mobile chips and AI-driven demand, while risks involve customer concentration, margin pressure, and legal scrutiny. The stock offers a dividend yield above 4%, supported by cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
